Document Detail


Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
MedLine Citation:
PMID:  17352685     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The phosphodiesterase (PDE) 4 is the predominant cyclic AMP degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes. In addition, this enzyme is expressed in non-immune cells such as keratinocytes and fibroblasts. Highly selective PDE4 inhibitors are currently under evaluation for the treatment of asthma and/or chronic obstructive pulmonary disease. Due to the broad anti-inflammatory/immuno-modulatory action of PDE4 inhibitors, it has been proposed that PDE4 inhibitors might also be efficacious for skin disorders such as atopic dermatitis. Consequently, PDE4 inhibitors including cilomilast and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation. These PDE4 inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the arachidonic acid induced skin inflammation in mice and in ovalbumin sensitised guinea pigs. The determination of cytokines in skin homogenates revealed that both Th1 as well as Th2 cytokines are suppressed by PDE4 inhibitors, indicating an anti-inflammatory activity in both the Th2 dominated acute phase as well as the Th1 dominated chronic phase of atopic dermatitis. Due to the suppression of Th1 cytokines, activity can also be expected in psoriasis. Results of early clinical trials with both topically (cipamfylline, CP80,633) and systemically (CC-10004) active PDE4 inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis. AWD 12-281 (GW 842470) is currently under clinical evaluation for the topical treatment of atopic dermatitis. Results concerning clinical efficacy of this potent and selective PDE4 inhibitor are anxiously awaited.
Authors:
Wolfgang Bäumer; Joachim Hoppmann; Chris Rundfeldt; Manfred Kietzmann
Related Documents :
25075215 - Adaptive immunity in cancer immunology and therapeutics.
21373265 - Heme oxygenase-1: a novel therapeutic target for gastrointestinal diseases.
16329645 - Cytokine targeting in psoriasis and psoriatic arthritis: beyond tnfalpha.
2419375 - Stress, symmetry, and psoriasis: possible role of neuropeptides.
18417115 - Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: f...
23347265 - Evidence for a role for the adaptive immune response in human term parturition.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Inflammation & allergy drug targets     Volume:  6     ISSN:  1871-5281     ISO Abbreviation:  Inflamm Allergy Drug Targets     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-03-13     Completed Date:  2007-04-25     Revised Date:  2011-11-10    
Medline Journal Info:
Nlm Unique ID:  101266886     Medline TA:  Inflamm Allergy Drug Targets     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  17-26     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Foundation, D-30559 Hannover, Germany. wolfgang.baeumer@tiho-hannover.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
Animals
Anti-Allergic Agents / pharmacology*,  therapeutic use*
Clinical Trials as Topic
Cyclic Nucleotide Phosphodiesterases, Type 4
Dermatitis, Allergic Contact / drug therapy*,  enzymology
Humans
Phosphodiesterase Inhibitors / pharmacology*,  therapeutic use*
Psoriasis / drug therapy*,  enzymology
Chemical
Reg. No./Substance:
0/Anti-Allergic Agents; 0/Phosphodiesterase Inhibitors; EC 3.1.4.17/3',5'-Cyclic-AMP Phosphodiesterases; EC 3.1.4.17/Cyclic Nucleotide Phosphodiesterases, Type 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives.
Next Document:  New insights on the nature of latent tuberculosis infection and its treatment.